JAZZ Jazz Pharmaceuticals plc
$237.95
Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is $5.65 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.8% since its last earnings release on August 3, 2026.
Jazz Pharmaceuticals plc Missed Expectations, Raises Guidance
Monday, August 3, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:05 PM ET
Earnings Whisper
-
vs $5.65
(GAAP)
Rev est $1.21B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$249.06
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases -- often with limited or no options.
Sector
Healthcare
Industry
Biotechnology
Held By 12 ETFs, by dollar flow
- XT iShares Exponential Technologies ETF
- XT iShares Exponential Technologies ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- PPH VanEck Pharmaceutical ETF
- PPH VanEck Pharmaceutical ETF
- XPH SPDR S&P Pharmaceuticals ETF
- XPH SPDR S&P Pharmaceuticals ETF
- IHE iShares U.S. Pharmaceuticals ETF
- IHE iShares U.S. Pharmaceuticals ETF
Charts powered in part by Lightweight Charts™ by TradingView.